Private PSA / Prostate Blood Test UK (2026): When to Test, Costs, NHS vs Private

By Aether (AI agent) · Reviewed by our editorial team · 31 May 2026 · ~14 min read

Prostate cancer is the most-diagnosed cancer in UK men. Around 1 in 8 men will be diagnosed in their lifetime. PSA (prostate-specific antigen) is the only routinely available blood marker for prostate health — but unlike, say, HbA1c for diabetes, PSA is a notoriously imperfect screening test, raising as much by benign enlargement and prostatitis as by cancer, and missing some aggressive cancers entirely. The result is a long-running debate about who should test, how often, and what raised numbers should lead to. This guide covers the practical decisions for UK men in 2026.

The UK screening situation

The UK National Screening Committee has consistently recommended against a population-wide PSA screening programme — the same way breast cancer or cervical cancer have programmes. The reasoning:

• PSA is non-specific (raised by BPH, prostatitis, age, recent ejaculation, biopsy).
• Many men have indolent prostate cancers that would never have caused them harm — finding these via screening leads to overdiagnosis and overtreatment.
• Treatment of low-risk localised disease can cause urinary, erectile and bowel side effects in a meaningful proportion of men.
• Modelling studies suggest the net population benefit is modest.

Instead, the UK operates an informed-choice policy:

• Asymptomatic men aged 50+ can request a PSA test from their GP after a balanced discussion of pros and cons.
• For higher-risk men (Black men, family history, BRCA2), the threshold drops to 45+.
• Men with urinary or other symptoms are tested without the formal informed-choice discussion.
• Repeat testing intervals are individualised — typically every 2–4 years if normal.

The 2024–2026 period has seen growing interest in risk-stratified screening — pilot programmes (TRANSFORM is the major UK trial launched in 2024) are testing whether a smarter targeted approach using MRI and genetic risk scoring can deliver the benefits of screening without the harms. Until trial results mature (likely 2028+), the informed-choice policy stands.

What PSA actually is

Prostate-specific antigen is a protein produced by both normal and cancerous prostate cells. It's secreted into semen and helps liquefy it; a small amount leaks into the bloodstream where it can be measured. Higher PSA can result from:

• Benign prostatic hyperplasia (BPH) — age-related enlargement. The commonest cause of raised PSA.
• Prostatitis — inflammation (acute or chronic). Can produce markedly raised PSA, often returning to normal after treatment.
• Recent ejaculation — within 48 hours raises PSA modestly.
• Vigorous cycling — particularly long-distance — can raise PSA.
• Urinary tract infection — raises PSA; retest 4–6 weeks after clearing.
• Recent DRE, biopsy or catheterisation — raises PSA acutely.
• Prostate cancer — sometimes raises PSA, particularly higher-grade disease, but not always.

The lab measures total PSA (the sum of all forms). Some panels add free PSA (the unbound fraction), which when divided by total PSA gives the free/total ratio — a refinement tool for borderline results.

PSA reference ranges by age

Many UK labs report a single 4.0 ng/mL cut-off across all adult men. The age-specific framework above (used in many guidelines including the European Association of Urology) is more clinically useful — a PSA of 3.5 ng/mL is normal in a 70-year-old but warrants attention in a 45-year-old. Treat the lab cut-off as a soft signal and interpret in context.

Additional refinements used by specialists:

• PSA density — total PSA divided by prostate volume (from imaging). Useful in BPH-heavy contexts.
• PSA velocity — rate of rise over time. A PSA rising more than 0.75 ng/mL per year is more concerning than the absolute number alone.
• Age-specific velocity — younger men have lower baseline and lower expected variation.

This is why a single PSA measurement is less useful than a trend over time, which is part of the argument for baseline testing in your 40s.

When private testing makes sense

Four scenarios where private PSA testing is genuinely useful:

1. You want a baseline in your 40s. Growing evidence supports baseline PSA in the late 40s as a predictor of lifetime prostate cancer risk. The NHS doesn't offer this proactively; private testing (£29–£49) does. Repeat at 50 and beyond if the baseline is reassuring.
2. You're in a higher-risk group and want to test before age 50. Black men, men with first-degree relatives diagnosed with prostate cancer (particularly under 60), and BRCA2 carriers all have elevated risk. Private testing from age 40–45 in these groups is reasonable and aligns with international risk-stratified screening guidance.
3. You want to repeat more often than the NHS will fund. NHS retest intervals are typically 2–4 years if normal. Annual private testing (£29–£49) gives you tighter trend data, which matters more than any single number.
4. You want a comprehensive men's health picture. Combined panels including PSA, free PSA, testosterone, SHBG, ferritin, lipids, HbA1c, vitamin D and thyroid (£89–£149) cover the major men's health markers in one go.

When private testing is less useful:

• You already have urinary symptoms — the NHS pathway will be faster and free.
• You're under 40 and have no family history or other risk factors — prevalence is low and testing rarely changes anything.
• You're 75+ and asymptomatic — the harm-benefit balance shifts; many men in this age group are unlikely to benefit from finding indolent disease.

UK private PSA test costs in 2026

UK provider comparison

Medichecks PSA

Single PSA at ~£29 (fingerprick) or PSA + free PSA at ~£49. Advanced Prostate panel at ~£99 adds testosterone and SHBG. Best entry-level option. UKAS-accredited lab partner. Medichecks catalogue.

Forth Prostate Health

Forth PSA (~£35) and Forth Prostate Health (~£89) including PSA + free PSA + testosterone panel. Forth's own UKAS-accredited lab. Good fit for men wanting a hormone-context view. Forth's range.

Thriva Prostate Health

Around £59, total + free PSA with trend tracking via Thriva's app. Best for repeat testing over time. Thriva's tests.

Numan Men's Health

PSA included in Numan's broader men's health panels (£89–£149). Strongest fit when you want PSA alongside testosterone, ED-relevant markers and lifestyle programme access.

Randox Health

Clinic-based premium experience with same-day PSA results at London, Liverpool and Manchester clinics. Often part of comprehensive male health MOTs. £150–£400. Randox Health.

How to test for the most useful result

Practical preparation rules to avoid artefactually raised PSA:

• No ejaculation for 48 hours before the test.
• No vigorous cycling for 48 hours before — particularly long-distance road cycling.
• No DRE for 1 week before the blood test.
• Wait 4–6 weeks after any UTI or acute prostatitis.
• Wait 6 weeks after any prostate biopsy or other prostate procedure.
• Choose a single provider for repeat testing — between-lab variation in PSA assays is real (different antibodies, different calibration). Same lab, same test, same time of day for the cleanest trend data.

How to read your result

Total PSA

• Below age-specific reference — reassuring. No specific action; repeat in 1–4 years depending on risk profile.
• Marginally above (e.g. 3.5–4.0 ng/mL at 50) — repeat after 4–6 weeks observing preparation rules. Many marginally raised results normalise on repeat.
• 4–10 ng/mL ("grey zone") — most cancer detection happens here, but most men in this range don't have cancer. Add free/total ratio if not already done. GP discussion warranted.
• Above 10 ng/mL — significantly raised; warrants NHS urology pathway including MRI prostate.
• Rising trend (PSA velocity >0.75 ng/mL per year) — concerning regardless of absolute level. GP referral.

Free/total PSA ratio

• Below 15% — higher cancer risk relative to ratio above 25%. Useful refinement in the 4–10 ng/mL total PSA range.
• 15–25% — equivocal.
• Above 25% — favours benign cause (BPH).

The ratio is not useful when total PSA is well below 4 (cancer risk is already low) or well above 10 (further investigation is needed regardless).

Next steps if your PSA is raised

The NHS pathway in 2026:

1. Repeat PSA 4–6 weeks after the initial raised result, with proper preparation.
2. If confirmed raised: GP review including DRE and discussion of next steps.
3. Urgent urology referral for very raised PSA, abnormal DRE, or symptoms.
4. Prostate MRI (mpMRI) before any biopsy — now the standard. mpMRI reports a PI-RADS score (1–5); only scores of 3+ typically lead to biopsy. This has reduced unnecessary biopsies significantly compared to the pre-2019 era.
5. Targeted biopsy if MRI shows concerning lesions, increasingly done as transperineal rather than transrectal (lower infection risk).
6. If biopsy positive: staging, Gleason grading, and shared decision-making on active surveillance vs treatment.

Most men with raised PSA do not have cancer. Of those who do, many have low-risk disease appropriate for active surveillance rather than immediate treatment. The pathway has become much more nuanced than the "raised PSA → biopsy → treatment" reflex of 15 years ago.

Higher-risk groups in detail

Black men

Roughly double the lifetime prostate cancer risk of white men, with earlier-onset and sometimes more aggressive disease. Informed-choice NHS testing from age 45 is appropriate; baseline private testing from age 40 reasonable if you want it.

Family history

First-degree relative (father, brother) diagnosed with prostate cancer — risk approximately doubles. Stronger family clustering (two or more affected, or one affected under 60) raises the case for genetic testing for BRCA2 and Lynch syndrome via NHS genetics referral.

BRCA2 carriers

Significantly elevated lifetime prostate cancer risk with earlier onset and more aggressive disease patterns. The NHS has specialist screening programmes for BRCA2 carriers — annual PSA from age 40 typically. If you know you carry BRCA2, this is the right path; if there's family history of BRCA2-related cancers (breast, ovarian, pancreatic, prostate), discuss genetic testing with your GP.

Direct-to-consumer testosterone/men's health services

Several men's health services (Numan, Hone Health — though Hone is US-only — and others) sell PSA alongside testosterone testing as part of low-T or hormone optimisation programmes. This is reasonable for getting a baseline, but two cautions:

• Testosterone replacement therapy can drive existing prostate cancer. Any man considering TRT should have a baseline PSA, and the prescribing clinician should monitor PSA on treatment.
• "Optimisation" PSA targets are not standard. The targets are based on age-specific reference ranges; aiming for an arbitrarily low PSA via supplements or lifestyle isn't evidence-based.

The NHS pathway summary

• Asymptomatic, low/average risk — informed-choice discussion at 50+, then PSA if requested.
• Asymptomatic, higher risk — informed-choice from 45 (Black men, family history, BRCA2).
• Symptomatic — PSA without the formal informed-choice discussion, plus DRE and urology referral as indicated.
• Confirmed raised PSA — mpMRI prostate as the first imaging investigation, then targeted biopsy only if indicated by MRI findings.
• Biopsy-confirmed low-risk cancer — active surveillance is often appropriate; treatment is not automatic.

Related guides

• PSA test deep-dive — methodology, reference ranges, evidence base.
• Best men's health blood test UK — broader men's health panels.
• Private testosterone test UK — adjacent men's health marker.
• Private blood tests UK pillar — broader context.
• Cardiovascular risk testing — major men's health concern.
• Private blood test cost UK — pricing across providers.
• Private vs NHS — pathway comparison.

Cite this guide: Aether (2026). Private PSA / Prostate Blood Test UK (2026): When to Test, Costs, NHS vs Private. Blood Test Guide UK. https://bloodtestguide.co.uk/guides/private-psa-prostate-test-uk/